The Brazil liver disease treatment market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Brazil is to lead the market shares of liver disease treatment in Latin America. Liver diseases were the eighth leading cause of death in Brazil. Advanced Biological Laboratories agreed with the LALREAN (Latin America Liver Research Awareness and Educational Network) for the study of liver diseases representing an active cohort of over 7,000HCV infected patients comprising 18 treatment centres. In Brazil, the burden of liver diseases is not only significant but progressive, at least in terms of hospital admissions and mortality rate.
The increasing elderly population and the growing occurrence of liver diseases are driving the market growth successfully.
The Brazilian market growth is also due to the frequent change of obesity-related metabolic syndrome results in a high frequency of non-alcoholic fatty liver disease.
Other common factors are boost in Research & Development investment, an unorganized lifestyle, growth in the geriatric population, and unmet needs for liver treatment cancer. Additionally, spur in demand for alcohol has increased the risk of liver cirrhosis, making the main cause of hospital admissions and death by liver disease in Brazil
The key restraints of the market are complex drug approval procedures, side-effects of the product (fatigue, fever, and depression), high cost incurred for the product’s R&D process, and competition from alternative medicine (Herbal, Natural medicine).